<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01568580</url>
  </required_header>
  <id_info>
    <org_study_id>GC8AIII</org_study_id>
    <nct_id>NCT01568580</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A</brief_title>
  <official_title>Open-label, Non-comparative, Multicenter, Phase III for Evaluation of Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Previously Treated Patients With Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the evaluation of efficacy and safety of GreenGene&#xD;
      (Recombinant Factor VIII).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physician's assessment of hemostatic effect for on-demand treatment</measure>
    <time_frame>12 months</time_frame>
    <description>Category: Exellent, Good, Moderate, None</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemostatic effect for major bleeding</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Category: Exellent, Good, Moderate, None</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>consumption amount of test drug</measure>
    <time_frame>up to 12 month or 100 exposure days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's self assessment of treatment</measure>
    <time_frame>12 months</time_frame>
    <description>Category: Exellent, Good, Moderate, None</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVIII Recovery(%)</measure>
    <time_frame>every 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVIII inhibitor incidence rate</measure>
    <time_frame>every 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of adverse events</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery study: prohylactic effects</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Category: Exellent, Good, Moderate, None</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>test drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GreenGene</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GreenGene</intervention_name>
    <description>Dose : 10 ~ 50IU/kg Administration method : intravenous infusion or bolus</description>
    <arm_group_label>test drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hemophilia A patients at least 12 years of age&#xD;
&#xD;
          -  At least 150 treatment exposure-days to previous FVIII products&#xD;
&#xD;
          -  FVIII≤2% at screening or diagnosis (FVIII≤1% for PK study)&#xD;
&#xD;
          -  CD4 Lympocyte cell count&gt;400/㎕&#xD;
&#xD;
          -  Patients willing to cooperate for the study&#xD;
&#xD;
          -  Patient's or legal guardian's consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  FVIII inhibitor(neutralizing antibody to FVIII)≥0.6 Bethesda Units&#xD;
&#xD;
          -  Coagulation disorders other than hemophilia A (e.g. Idiopathic Thrombocytopenic&#xD;
             Purpura, von Willebrand Disease)&#xD;
&#xD;
          -  Platelet count≤100,000㎣&#xD;
&#xD;
          -  Subjects with clinical evidence of symptomatic HIV disease regardless of&#xD;
             HIV-seroposive/seronegative&#xD;
&#xD;
          -  Subjects with rFVIII antibody, mouse IgG antibody, or CHO antibody&#xD;
&#xD;
          -  Creatinine levels more than 2 times of reference rage, GOT and GPT levels more than 3&#xD;
             times of reference range, diabetes mellitus or other metabolic disorder&#xD;
&#xD;
          -  Subjects with diastolic blood pressure≥100mmHg not controlled with antihypertensive&#xD;
             medications&#xD;
&#xD;
          -  Anemia(hemoglobin&lt;12g/dL)&#xD;
&#xD;
          -  Subjects with severe or life-threatening bleeding just before entry into the trial&#xD;
&#xD;
          -  Subjects with a history of treatment failure due to formation of inhibitor to FVIII&#xD;
&#xD;
          -  Subjects with a history of severe hypersensitive reactions to FVIII concentrate&#xD;
&#xD;
          -  Subjects requiring pre-medication for FVIII infusion(e.g. antihistamines, etc)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>March 22, 2012</study_first_submitted>
  <study_first_submitted_qc>March 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2012</study_first_posted>
  <last_update_submitted>March 29, 2012</last_update_submitted>
  <last_update_submitted_qc>March 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemophilia A</keyword>
  <keyword>Factor VIII</keyword>
  <keyword>Recombinant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

